Sabin’s President, Dr. Peter Hotez, received the 2015 RESULTS Seeds of Hope Award on Sunday in Houston, Texas. Each year, this award honors a person in the Houston community who has made extraordinary contributions towards improving health, education or microfinance — the three pillars of RESULTS advocacy. This year’s award honored advances in Child and Maternal Health.

My role as a U.S. Science Envoy in 2015 has focused on a worrisome trend that became especially obvious following the emergence of the Ebola virus infection in West Africa last year.

New Partnership with India Aims to Build Vaccine Manufacturing Network for Hookworm, Other Diseases

WASHINGTON, D.C., BANGALORE, AMSTERDAM — October 14, 2015 — The Amsterdam Institute for Global Health and Development (AIGHD) and Sabin Vaccine Institute Product Development Partnership (Sabin PDP) today announced a new research and innovation partnership with the Association of Biotechnology Led Enterprises (ABLE) of India on vaccine development for hookworm and other neglected tropical diseases (NTDs). The European Union, through its EuropeAid program, recently awarded a five-year grant of €333,000 to AIGHD to establish this EU-India partnership.

The initial research for the Ebola vaccine was published in 2003, where it sat for more than a decade waiting for a vaccine manufacturer to invest in licensing and development. Only after the 2014 outbreak began did the U.S.

by Peter Hotez, M.D., Ph.D. Hotez is Dean of the National School of Tropical Medicine at Baylor College of Medicine where he is also the Texas Children’s Hospital Endowed Chair in Tropical Pediatrics and the University Professor of Biology at Baylor University.